317 related articles for article (PubMed ID: 29981816)
1. EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.
Soundararajan R; Paranjape AN; Maity S; Aparicio A; Mani SA
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):229-238. PubMed ID: 29981816
[TBL] [Abstract][Full Text] [Related]
2. Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer.
Li P; Yang R; Gao WQ
Mol Cancer; 2014 Mar; 13():55. PubMed ID: 24618337
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.
Sun Y; Wang BE; Leong KG; Yue P; Li L; Jhunjhunwala S; Chen D; Seo K; Modrusan Z; Gao WQ; Settleman J; Johnson L
Cancer Res; 2012 Jan; 72(2):527-36. PubMed ID: 22108827
[TBL] [Abstract][Full Text] [Related]
4. Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling.
Pandian V; Ramraj S; Khan FH; Azim T; Aravindan N
Stem Cell Res Ther; 2015 Feb; 6(1):2. PubMed ID: 25888913
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs and epithelial-mesenchymal transition in prostate cancer.
Sekhon K; Bucay N; Majid S; Dahiya R; Saini S
Oncotarget; 2016 Oct; 7(41):67597-67611. PubMed ID: 27588490
[TBL] [Abstract][Full Text] [Related]
6. Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer.
Dong B; Miao J; Wang Y; Luo W; Ji Z; Lai H; Zhang M; Cheng X; Wang J; Fang Y; Zhu HH; Chua CW; Fan L; Zhu Y; Pan J; Wang J; Xue W; Gao WQ
Commun Biol; 2020 Dec; 3(1):778. PubMed ID: 33328604
[TBL] [Abstract][Full Text] [Related]
7. Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.
Nouri M; Caradec J; Lubik AA; Li N; Hollier BG; Takhar M; Altimirano-Dimas M; Chen M; Roshan-Moniri M; Butler M; Lehman M; Bishop J; Truong S; Huang SC; Cochrane D; Cox M; Collins C; Gleave M; Erho N; Alshalafa M; Davicioni E; Nelson C; Gregory-Evans S; Karnes RJ; Jenkins RB; Klein EA; Buttyan R
Oncotarget; 2017 Mar; 8(12):18949-18967. PubMed ID: 28145883
[TBL] [Abstract][Full Text] [Related]
8. Regulation of tumor cell plasticity by the androgen receptor in prostate cancer.
Bishop JL; Davies A; Ketola K; Zoubeidi A
Endocr Relat Cancer; 2015 Jun; 22(3):R165-82. PubMed ID: 25934687
[TBL] [Abstract][Full Text] [Related]
9. Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer.
Garg M
Cancer Metastasis Rev; 2015 Dec; 34(4):691-701. PubMed ID: 26328525
[TBL] [Abstract][Full Text] [Related]
10. Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.
Zamora I; Freeman MR; Encío IJ; Rotinen M
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37761978
[TBL] [Abstract][Full Text] [Related]
11. Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation.
Merkens L; Sailer V; Lessel D; Janzen E; Greimeier S; Kirfel J; Perner S; Pantel K; Werner S; von Amsberg G
J Exp Clin Cancer Res; 2022 Feb; 41(1):46. PubMed ID: 35109899
[TBL] [Abstract][Full Text] [Related]
12. A novel spontaneous model of epithelial-mesenchymal transition (EMT) using a primary prostate cancer derived cell line demonstrating distinct stem-like characteristics.
Harner-Foreman N; Vadakekolathu J; Laversin SA; Mathieu MG; Reeder S; Pockley AG; Rees RC; Boocock DJ
Sci Rep; 2017 Jan; 7():40633. PubMed ID: 28094783
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies.
Conteduca V; Aieta M; Amadori D; De Giorgi U
Crit Rev Oncol Hematol; 2014 Oct; 92(1):11-24. PubMed ID: 24952997
[TBL] [Abstract][Full Text] [Related]
14. [Epithelial mesenchymal transition in prostate cancer: Advances in current research].
Yan B; Jiang N; Niu YJ
Zhonghua Nan Ke Xue; 2015 Sep; 21(9):847-51. PubMed ID: 26552221
[TBL] [Abstract][Full Text] [Related]
15. Loss of miR-100 enhances migration, invasion, epithelial-mesenchymal transition and stemness properties in prostate cancer cells through targeting Argonaute 2.
Wang M; Ren D; Guo W; Wang Z; Huang S; Du H; Song L; Peng X
Int J Oncol; 2014 Jul; 45(1):362-72. PubMed ID: 24805183
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression.
Ye X; Weinberg RA
Trends Cell Biol; 2015 Nov; 25(11):675-686. PubMed ID: 26437589
[TBL] [Abstract][Full Text] [Related]
17. Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention.
Nouri M; Ratther E; Stylianou N; Nelson CC; Hollier BG; Williams ED
Front Oncol; 2014; 4():370. PubMed ID: 25566507
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
19. Clonal Evolution and Epithelial Plasticity in the Emergence of AR-Independent Prostate Carcinoma.
Laudato S; Aparicio A; Giancotti FG
Trends Cancer; 2019 Jul; 5(7):440-455. PubMed ID: 31311658
[TBL] [Abstract][Full Text] [Related]
20. ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features.
Albino D; Longoni N; Curti L; Mello-Grand M; Pinton S; Civenni G; Thalmann G; D'Ambrosio G; Sarti M; Sessa F; Chiorino G; Catapano CV; Carbone GM
Cancer Res; 2012 Jun; 72(11):2889-900. PubMed ID: 22505649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
